Brady-Nicholls, Renee http://orcid.org/0000-0003-1759-8283
Nagy, John D.
Gerke, Travis A.
Zhang, Tian
Wang, Andrew Z. http://orcid.org/0000-0002-9781-4494
Zhang, Jingsong
Gatenby, Robert A.
Enderling, Heiko http://orcid.org/0000-0002-9696-6410
Funding for this research was provided by:
Ocala Royal Dames for Cancer Research The Jayne Koskinas Ted Giovanis Foundation for Health and Policy
Ocala Royal Dames for Cancer Research, Inc. The Jayne and Ted Giovanis Foundation for Health and Policy
Article History
Received: 9 May 2019
Accepted: 9 March 2020
First Online: 9 April 2020
Competing interests
: Provisional patent application entitled “Methods for PCa intermittent adaptive therapy”. Applicants/inventors: Renee Brady-Nicholls, Heiko Enderling; application number: 62/944.804; status: provisionally filed. The patent covers methods related to using the mathematical model to adjust an individual patient’s treatment administration (both timing and alternative treatment options), thereby increasing TTP. T.Z.: Research funding: Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeneron, Mirati Therapeutics, Janssen, Astra Zeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, Seattle Genetics; Speakers Bureau: Genentech/Roche, Exelixis, Sanofi-Aventis, Genomic Health; Advisory Board: Genentech/Roche, Merck, Exelixis, Sanofi-Aaventis, Janssen, Astra Zeneca, Pfizer, Amgen, BMS, Pharmacyclics, Seattle Genetics, Bayer; Consultant: Bayer, Astra Zeneca, Foundation Medicine; Employee: Capio Biosciences, Archimmune Therapeutics (spouse); Stockholder: Capio Biosciences, Archimmune Therapeutics (spouse); A.Z.W.: Cofounder, stockholder and consultant: Capio Biosciences, Archimmune Therapeutics; J.Z.: Consultant: Dendreon, Advisory Board: AstraZeneca, Bayer, Clovis Oncology, Seattle Genetics, Speaker Bureau: Merck, Sanofi. All other authors declare no competing interests.